Hair loss in women guide: causes, diagnosis, and the evidence-based treatment approach
A complete guide to hair loss in women — the multiple distinct causes of female hair loss, how to distinguish them clinically, the diagnostic work-up, and the evidence-based medical and procedural treatment options for each cause.
· By MedSpot Editorial · 7 min read
Female hair loss is significantly more diagnostically complex than male pattern hair loss. While the majority of male hair loss is androgenetic alopecia following a predictable course, women presenting with hair loss require a broader differential — multiple distinct conditions commonly co-occur, and treating one without identifying the others leaves the hair loss partially uncorrected. Here's the complete diagnostic and treatment framework.
Why female hair loss is different
The male vs. female AGA contrast
In men, androgenetic alopecia (AGA) is the dominant cause of hair loss in approximately 95% of cases and follows a characteristic frontal recession + vertex loss pattern (Norwood-Hamilton scale). The diagnosis is usually clinical.
In women:
- AGA is still common (affecting ~40% of women by age 70) but presents differently — diffuse crown thinning with preserved frontal hairline (Ludwig classification) rather than frontal recession
- Multiple other causes frequently co-occur with or mimic AGA
- Hormonal causes (thyroid, PCOS, postpartum, peri/postmenopausal changes) are common
- Nutritional deficiencies, particularly iron, are far more prevalent in premenopausal women than men
- Autoimmune conditions (alopecia areata, lichen planopilaris) occur more commonly in women
The clinical imperative: A comprehensive work-up is essential for every woman presenting with hair loss — a single blood test finding a treatable cause can resolve years of ineffective symptomatic treatment.
The diagnostic framework: pattern recognition
Diffuse hair loss (loss from all over the scalp)
Differential: Telogen effluvium (TE), AGA, thyroid dysfunction, nutritional deficiency (iron, zinc, vitamin D, protein), PCOS, postpartum, other hormonal causes, medications
Clinical features:
- Hair lost from all scalp zones, not a specific pattern
- Shed hairs have white telogen bulbs at the root (physiological shed, not broken)
- Hair count typically >150/day consistently
- May reveal underlying scalp (but no bald patches)
Patterned thinning (specific scalp zones affected)
Female AGA:
- Ludwig pattern: Diffuse thinning concentrated at the crown/vertex; widening of the central part; frontal hairline typically preserved
- Dermoscopy: miniaturized (fine, short) hairs visible in the affected area — the hallmark of AGA
- Chronic, progressive course; no episodic trigger
Frontal fibrosing alopecia (FFA):
- Progressive recession of the frontal/temporal hairline in a band-like pattern
- Scalp is pale/ivory at the recession line; perifollicular erythema and scale at the margin
- Loss of eyebrows and body hair in many cases
- Primary cicatricial (scarring) alopecia — permanent if untreated
Central centrifugal cicatricial alopecia (CCCA):
- Scarring hair loss beginning at the crown and expanding centrifugally
- Most common in Black women; associated with certain hairstyling practices historically (hot combing), though the association is complex and may also involve genetic predisposition
- Progressive; requires prompt treatment to slow scarring
Patchy hair loss (discrete bald areas)
Alopecia areata:
- Well-demarcated, smooth bald patches; round or oval
- Exclamation-point hairs (hairs that taper at the base) at patch margins on dermoscopy — pathognomonic
- Immune-mediated; can progress to alopecia totalis (complete scalp loss) or universalis (all body hair)
Traction alopecia:
- Pattern follows the direction and location of tension (frontal/temporal hairline with tight ponytails; along braid lines)
- Reversible in early stages; permanent once fibrosis occurs
Tinea capitis:
- Fungal infection; more common in children but occurs in adults
- Scaling, broken-off hairs, sometimes kerion (inflammatory mass)
- Requires oral antifungal therapy
Key causes in detail
Female AGA (androgenetic alopecia)
Mechanism: Identical to male AGA — DHT-driven follicular miniaturization in androgen-receptor-sensitive follicles — but women typically have lower androgen levels and fewer androgen receptors in the frontal zone (explaining why women retain the frontal hairline while men lose it). The Ludwig pattern reflects the distribution of AR-sensitive follicles in women.
Hormonal evaluation: Unlike male AGA, female AGA warrants hormonal assessment to rule out androgen excess:
- Free testosterone (and total testosterone)
- DHEA-S (dehydroepiandrosterone sulfate) — androgen from the adrenal gland
- Prolactin (hyperprolactinemia → hormonal disruption → hair loss)
- FSH / LH ratio (PCOS assessment)
Dermoscopy: The most reliable clinical tool — miniaturized hairs (fine, short, light-colored) in the crown/vertex zone confirm AGA pattern; this distinguishes AGA from TE (where hairs are normal caliber but fewer).
Telogen effluvium (TE)
Mechanism: A stressor 2–4 months prior pushes follicles prematurely into telogen → synchronized mass shedding. Common triggers in women: childbirth, major illness, significant weight loss/calorie restriction, iron deficiency, thyroid dysfunction, stopping hormonal contraception, psychological stress, COVID-19 infection.
Distinguishing from AGA:
- TE: acute onset with identifiable trigger ~3 months prior; diffuse; normal hair caliber on dermoscopy; often self-resolving
- AGA: chronic, progressive; miniaturized hairs on dermoscopy; crown predominance
Chronic TE: Defined as diffuse shedding persisting >6 months without a clear single triggering event. Requires comprehensive work-up; often reveals iron deficiency, thyroid dysfunction, or underlying AGA driving the chronicity.
PCOS-related hair loss
Polycystic ovary syndrome (PCOS) affects approximately 10% of premenopausal women and is associated with:
- Androgenic hair loss (AGA-type scalp loss) — elevated androgens drive follicular miniaturization
- Hirsutism (excess facial/body hair) — the same androgens that cause scalp AGA stimulate facial follicles
- Irregular menstruation, acne, metabolic features
Assessment: Free testosterone, DHEA-S, LH/FSH ratio, pelvic ultrasound (polycystic ovary morphology)
Treatment overlap: Anti-androgen medications used for PCOS (spironolactone, combined oral contraceptives with anti-androgenic progestins) also treat the AGA component.
Postpartum hair loss
Discussed in detail in the postpartum hair loss guide — the estrogen-withdrawal synchronized TE that peaks at months 3–4 postpartum, co-occurring with iron depletion and occasionally postpartum thyroiditis. The key evaluation in persistent postpartum hair loss is ferritin level and TSH.
Menopausal and perimenopausal hair loss
The estrogen decline of perimenopause removes the anagen-prolonging effect of estrogen → shortened anagen → more follicles cycling into telogen. Simultaneously, relative androgen excess (as estrogen falls more than androgens) drives AGA progression in genetically predisposed women.
Evaluation: TSH (postmenopausal thyroiditis is common), ferritin, free testosterone, FSH (confirms menopause stage).
Diagnostic work-up: the full panel
| Test | Rationale |
|---|---|
| Serum ferritin | Most common correctable cause; target >70 ng/mL |
| CBC | Anemia; nutritional overview |
| TSH + free T4 | Thyroid — both hypo and hyperthyroid cause TE |
| Free testosterone + total testosterone | AGA + PCOS androgen excess |
| DHEA-S | Adrenal androgen excess |
| Prolactin | Hyperprolactinemia causes anovulation and hair loss |
| LH / FSH | PCOS (LH:FSH ratio >2:1 suggestive); menopause staging |
| 25-OH Vitamin D | Very common deficiency |
| Serum zinc | Vegetarians, GI conditions |
| B12 | Vegans, elderly, metformin users |
| ANA + anti-TPO | Autoimmune screen if alopecia areata, lichen planopilaris, or thyroiditis suspected |
| Zinc / copper | If zinc supplementation history; eating disorder |
Dermoscopy: A dermatologist or trichologist using dermoscopy can assess: miniaturization pattern (AGA), exclamation-point hairs (AA), perifollicular scale and erythema (cicatricial alopecias), and hair cycle distribution. This is the most informative single non-blood assessment.
Scalp biopsy: In unclear cases — particularly suspected cicatricial (scarring) alopecias (FFA, LPP, CCCA) — a 4-mm punch biopsy for horizontal sectioning provides definitive histological diagnosis. Essential before initiating aggressive therapy for suspected scarring alopecia.
Evidence-based treatments by cause
Female AGA
Minoxidil (topical or oral): First-line. Topical 2% or 5% (foam preferred for women to reduce facial hypertrichosis); low-dose oral minoxidil 0.625–1.25 mg/day is increasingly used for superior adherence and scalp distribution. See the minoxidil guide for full mechanism and protocol.
Spironolactone (oral anti-androgen): Off-label for female AGA; 50–200 mg/day. Androgen receptor antagonist + 5AR inhibitor activity → reduces DHT-driven miniaturization. Roberts et al. (2021, British Journal of Dermatology — the SISTA trial): randomized comparison vs. minoxidil in women with female pattern hair loss — spironolactone non-inferior to minoxidil at 12 months for a proportion of responders; some patients responded better to one vs. the other.
Finasteride: 2.5 mg/day off-label for postmenopausal women (contraindicated in premenopausal women without reliable contraception due to teratogenicity risk for male fetuses).
Hair transplantation: FUE in women with stable AGA and adequate donor density; same principles as male transplant but women's AGA pattern (diffuse crown thinning) sometimes makes donor zone identification more complex.
Telogen effluvium
Correct the underlying cause: iron deficiency (ferritin correction to >70 ng/mL), thyroid normalization, nutritional rehabilitation, stress management. Minoxidil as an adjunct during recovery if prolonged.
Alopecia areata
Intralesional triamcinolone acetonide (5–10 mg/mL) for limited/patchy disease — most effective first-line for < 50% scalp involvement. JAK inhibitors (baricitinib FDA-approved 2022, ritlecitinib 2023) for severe/extensive alopecia areata — the first systemic treatments with proven efficacy for moderate-to-severe AA. Topical immunotherapy (DPCP, squaric acid) for moderate disease.
Frontal fibrosing alopecia / lichen planopilaris
Hydroxychloroquine 200–400 mg/day as systemic anti-inflammatory; topical/intralesional steroids for active inflammation at the margin; JAK inhibitors in refractory cases; 5AR inhibitors (finasteride/dutasteride) may slow FFA progression. Early treatment is critical — scarring is irreversible.
CCCA
Anti-inflammatory treatment (tetracycline-class antibiotics for some cases, topical steroids); address potential contributing factors; anti-androgen therapy for hormonal contributions; early referral to dermatologist specializing in scalp disease.
Looking for a hair loss consultation? Browse hair restoration providers on MedSpot →